Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04193293 · ClinicalTrials.gov registry record · Phase 1
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
A Phase 1 study, sponsored by SecuraBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04193293 is a Phase 1 study that was terminated before completion, run by SecuraBio. The registered enrollment target is 2 participants.
The verdict
NCT04193293, a Phase 1 study, was terminated before completion, sponsored by SecuraBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Duvelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2020-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04193293
The ClinicalTrials.gov registry entry for NCT04193293 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SecuraBio, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04193293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04193293 about?
NCT04193293 is a clinical study titled "A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer". This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
What is the current status of trial NCT04193293?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2020-06-01. Estimated completion is 2020-12-10.
What interventions are being tested in trial NCT04193293?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Duvelisib (DRUG).
Who is sponsoring clinical trial NCT04193293?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.